Loading...
XNAS:SRPT
Sarepta Therapeutics shares are trading higher after the FDA recommended removing Elevidys' voluntary clinical hold in ambulatory DMD patients, with BMO and Barclays upgrading their price targets to $50 and $22, respectively.
Sarepta Therapeutics shares are trading lower after Barclays downgraded the stock to 'Underweight' with a price target of $10, citing concerns over liquidity and regulatory issues following multiple patient deaths linked to its Elevidys therapy, which also led to multiple class-action lawsuits against the company.
Sarepta Therapeutics shares are trading lower after The Gross Law Firm announced a class action lawsuit alleging misleading statements about the safety risks of its gene therapy product, Elevidys. Additionally, RBC cut its price target on Sarepta from $23 to $10, citing a challenging path forward for the company.
Sarepta Therapeutics shares are trading lower after multiple law firms filed class action lawsuits concerning safety issues with its product ELEVIDYS, following reports of patient deaths. Analysts have further compounded the negative sentiment with several downgrades, including Morgan Stanley cutting its price target to $15, while H.C. Wainwright sees zero intrinsic value, indicating a major loss of confidence in the stock's value.
Sarepta Therapeutics shares are trading lower after the company faced a class action lawsuit related to allegations of false statements and safety risks of its gene therapy, ELEVIDYS, which has led to patient deaths. RBC Capital cut its price target for Sarepta to $23, maintaining a Sector Perform rating, citing demand pressures and regulatory uncertainties.
Sarepta Therapeutics shares are trading lower after Piper Sandler downgraded its price target from $36 to $32 and Leerink Partners cut their target from $50 to $45, amidst ongoing securities class action lawsuits related to the ELEVIDYS treatment.
Sarepta Therapeutics shares are trading lower after BMO Capital downgraded the stock to Market Perform with a reduced price target of $70, citing safety concerns related to their Elevidys treatment. Additionally, Piper Sandler downgraded their rating to Neutral with a lowered price target of $36.